新型组合性自抑制疗法用于三阴性乳腺癌
Yomna S Abd El-Aziz1, Taymin du Toit-Thompson2, Matthew J McKay3
1Northern Clinical School, Faculty of Medicine and Health, University of Sydney, Australia; Kolling Institute of Medical Research, University of Sydney, Australia; Oral Pathology Department, Faculty of Dentistry, Tanta University, Tanta, Egypt.
European journal of pharmacology
|April 11, 2024
概括
用新型药物组合向自显示出治疗三阴性乳腺癌 (TNBC) 的前景. 这种方法抑制了敏感和耐药TNBC模型中的瘤细胞增殖,提供了一种新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 分子医学是分子医学.
背景情况:
- 由于治疗选择有限,三阴性乳腺癌 (TNBC) 的预后不佳.
- 自与激进的TNBC行为和患者的不良结果有关.
- 这项研究调查了向自作为一种新的策略,以打击TNBC进展.
研究的目的:
- 探索自在TNBC进展中的作用.
- 评估用于TNBC治疗的新型自抑制剂.
- 为了确定自抑制剂的协同作用组合.
主要方法:
- 通过使用免疫阻塞和显微镜检查了微环境压力因素的自诱导.
- 评估了自抑制剂和化疗的扩散和迁移效应.
- 利用体内异种移植模型和蛋白质组分析来研究化学抵抗机制.
主要成果:
- 代谢性压力诱导TNBC细胞系的自.
- 自抑制剂SAR405和MRT68921显示出协同作用的抗增殖作用.
- 与预期相反,LC3表达与更好的TNBC患者存活率相关.
结论:
- 一种新的自抑制剂组合有效地抑制了TNBC细胞的增殖.
- 这种组合显示出作为TNBC的新治疗方式的潜力.
- 对自调节的进一步研究可能会导致改善TNBC疗法.
相关概念视频
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy
522
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
522
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
The Intrinsic Apoptotic Pathway
6.5K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.5K


